Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro

Vaccine

Volumn 21, Issue 9-10, 2003, Pages 849-855

  Sun, Hongfan ^a   Pollock, Kevin G J ^a   Brewer, James M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Adjuvant; Antigen presentation; Dendritic cell

Indexed keywords

ALUMINUM HYDROXIDE; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OVALBUMIN; POLYGLACTIN; SURFACTANT;

ANIMAL CELL; ANTIGEN PRESENTATION; BONE MARROW; CELL ACTIVATION; CONFERENCE PAPER; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; DRUG FORMULATION; HYBRIDOMA CELL CULTURE; LIPID VESICLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS; DENDRITIC CELLS; HYBRIDOMAS; KINETICS; LACTIC ACID; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; OVALBUMIN; POLYGLYCOLIC ACID; POLYMERS; SURFACE-ACTIVE AGENTS; T-LYMPHOCYTES; VACCINES;

EID: 0037435833     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00531-5     Document Type: Article

References (43)

1. Lafferty K.J., Prowse S.J., Simeonovic C.J., Warren H.S. Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Annu. Rev. Immunol. 1:1983;143-173.
2. Mueller D.L., Jenkins M.K., Schwartz R.H. Clonal expansion versus clonal inactivation: a co-stimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7:1989;481-511.
3. Curtsinger J.M., Schmidt C.S., Mondino A.et al. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J. Immunol. 162(6):1999;3256-3262.
4. Khoruts A., Mondino A., Pape K.A., Reiner S.L., Jenkins M.K. A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism. J. Exp. Med. 187(2):1998;225-236.
5. Brewer J.M., Alexander J. Cytokines and the mechanisms of action of vaccine adjuvants. Cytokines, Cell. Mol. Ther. 3(4):1997;233-246.
6. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., BenEfraim S., Gupta C.K. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine. 11(3):1993;293-306.
7. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392(6673):1998;245-252.
8. Banchereau J., Briere F., Caux C.et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:2000;767-811.
9. Poltorak A., He X., Smirnova I.et al. Defective LPS signalling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 282(5396):1998;2085-2088.
10. Hemmi H., Takeuchi O., Kawai T.et al. A toll-like receptor recognises bacterial DNA. Nature. 408(6813):2000;740-745.
11. Brewer J.M., Conacher M., Mohrs M., Brombacher F., Alexander J. Aluminium hydroxide adjuvant initiates strong antigen specific Th2 responses in the absence of IL-4 or IL-13 mediated signalling. J. Immunol. 163(12):1999;6448-6454.
12. Brewer J.M., Conacher M., Satoskar A., Bluethmann H., Alexander J. In interleukin-4 deficient mice, alum not only generates T helper-1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper-2 cytokine production. Eur. J. Immunol. 26(9):1996;2062-2066.
13. Brewer J.M., Alexander J. The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin. Immunology. 75(4):1992;570-575.
14. Brewer J.M., Roberts C.W., Conacher M., McColl J., Blaney B.A., Alexander J. An adjuvant formulation which preferentially induces Th1 cytokine and CD8+ cytotoxic responses is associated with up-regulation of IL-12 and suppression of IL-10 production. Vaccine Res. 5(2):1996;77-89.
15. O'Hagan D.T., McGee J.P., Holmgren J.et al. Biodegradable microparticles for oral immunisation. Vaccine. 11(2):1993;149-154.
16. O'Hagan D.T., Rahman D., McGee J.P.et al. Biodegradable microparticles as controlled release antigen delivery systems. Immunology. 73(2):1991;239-242.
17. Underhill D.M., Bassetti M., Rudensky A., Aderem A. Dynamic interactions of macrophages with T cells during antigen presentation. J. Exp. Med. 190(12):1999;1909-1914.
18. Brewer J.M., Tetley L., Richmond J., Liew F.Y., Alexander J. Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen. J. Immunol. 161(8):1998;4000-4007.
19. Brewer J.M., Roberts C.W., Stimson W.H., Alexander J. Accurate determination of adjuvant-associated protein or peptide by ninhydrin assay. Vaccine. 13(15):1995;1441-1444.
20. Newman K.D., Samuel J., Kwon G. Ovalbumin peptide encapsulated in poly(D, L-lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response. J. Control Release. 54(1):1998;49-59.
21. Lutz M.B., Kukutsch N., Ogilvie A.L.et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods. 223(1):1999;77-92.
22. Guery J.C., Ria F., Galbiati F., Smiroldo S., Adorini L. The mode of protein antigen administration determines preferential presentation of peptide-Class II complexes by lymph node dendritic or B cells. Int. Immunol. 9(1):1997;9-15.
23. Schijns V.E. Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol. 12(4):2000;456-463.
24. Steinman R.M., Pope M. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 109(12):2002;1519-1526.
25. Austyn JM. Dendritic cells: nature's adjuvants. In: Gregoriadis G, McCormack B, Allison AC, Poste G, editors. New generation vaccines. The role of basic immunology. New York: Plenum Press Life Sciences; 1993. p. 1-10.
26. Sallusto F., Cella M., Danieli C., Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class-II compartment - down-regulation by cytokines and bacterial products. J. Exp. Med. 182(2):1995;389-400.
27. De Smedt T., Pajak B., Muraille E.et al. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J. Exp. Med. 184(4):1996;1413-1424.
28. De Becker G., Moulin V., Pajak B.et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int. Immunol. 12(6):2000;807-815.
29. Tapping R.I., Akashi S., Miyake K., Godowski P.J., Tobias P.S. Toll-like receptor 4, but not toll-like receptor 2, is a signalling receptor for Escherichia and Salmonella lipopolysaccharides. J. Immunol. 165(10):2000;5780-5787.
30. Janeway CA. Approaching the asymptote? Evolution and revolution in immunology. In: Proceedings of the Cold Spring Harbor Symposia on Quantitative Biology, Cold Spring Harbor, vol. 54, issue 1, 1989. p. 1-13.
31. Gallucci S., Lolkema M., Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5(11):1999;1249-1255.
32. Morein B., Sundquist B., Hoglund S., Dalsgaard K., Osterhaus A. ISCOM, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature. 308(5958):1984;457-459.
33. Rajananthanan P., Attard G.S., Sheikh N.A., Morrow W.J. Novel aggregate structure adjuvants modulate lymphocyte proliferation and Th1 and Th2 cytokine profiles in ovalbumin immunised mice. Vaccine. 18(1-2):1999;140-152.
34. Brewer J.M., Alexander J. Studies on the adjuvant activity of non-ionic surfactant vesicles: adjuvant driven IgG2a production independent of MHC control. Vaccine. 12(7):1994;613-619.
35. Dupuis M., Murphy T.J., Higgins D.et al. Dendritic cells internalise vaccine adjuvant after intra-muscular injection. Cell Immunol. 186(1):1998;18-27.
36. Dupuis M., Denis-Mize K., LaBarbara A.et al. Immunisation with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur. J. Immunol. 31(10):2001;2910-2918.
37. Brewer JM, Roberts CW, O'Grady JE, Smart CJ, Alexander J. Non-ionic surfactant vesicles as vaccine delivery systems. In: Proceedings of the Second Conference on Industrial Immunology, Brighton, 1994. p. 34-6 [Chapter 20].
38. Smith J.B., McIntosh G.H., Morris B. The traffic of cells through tissues: a study of peripheral lymph in sheep. J. Anat. 107(1):1970;87-100.
39. Harmsen A.G., Muggenburg B.A., Snipes M.B., Bice D.E. The role of macrophages in particle translocation from lungs to lymph nodes. Science. 230(4731):1985;1277-1280.
40. Randolph G.J., Inaba K., Robbiani D.F., Steinman R.M., Muller W.A. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity. 11(6):1999;753-761.
41. Mannhalter J.W., Neychev H.O., Zlabinger G.J., Ahmad R., Eibl M.M. Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clin. Exp. Immunol. 61(1):1985;143-151.
42. Dal Monte P.R., Szoka F.C. Jr. Effect of liposome encapsulation on antigen presentation in vitro: comparison of presentation by peritoneal macrophages and B cell tumors. J. Immunol. 142(5):1989;1437-1443.
43. Harding C.V., Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by Class I MHC molecules. J. Immunol. 153(11):1994;4925-4933.